S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL

Bibliographic Details
Main Authors:	Arnon Kater, Julie Dubois, Christian Brieghel, Sabina Kersting, Lisbeth Enggaard, Gerrit Veldhuis, Rogier Mous, Clemens Mellink, Johan Dobber, Christian Poulsen, Caspar Da Cunha-Bang, Hendrik Fredriksen, Ann Janssens, Ida Schjodt, Ellen Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Mark-David Levin, Carsten Niemann
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967504.10648.ed

Similar Items

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
by: Aleksandra Urban, et al.
Published: (2023-08-01)

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months
by: Thomas E. Lew, et al.
Published: (2020-01-01)

P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
by: Sabina Kersting, et al.
Published: (2023-08-01)

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
by: Carsten Utoft Niemann, et al.
Published: (2020-10-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
by: Karoline Kielbassa, et al.
Published: (2023-08-01)

Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient
by: Kim Abbegail Tan Aldecoa, et al.
Published: (2023-01-01)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
by: Natalia Timofeeva, et al.
Published: (2021-04-01)

REAL-WORLD ANALYSIS OF PATIENTS WITH CLL TREATED WITH IBRUTINIB: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN REGISTRY OF CLL
by: V Pfister, et al.
Published: (2024-10-01)

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
by: P. Hillmen, et al.
Published: (2022-06-01)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
by: Annamaria Mascolo, et al.
Published: (2023-08-01)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
by: Joanne E. Davis, et al.
Published: (2021-11-01)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
by: Lydia Scarfò, et al.
Published: (2023-08-01)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
by: Gianluigi Reda, et al.
Published: (2018-06-01)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
by: Timothy L. Chen, et al.
Published: (2021-02-01)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
by: Gabriela Galicia-Vázquez, et al.
Published: (2018-09-01)

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
by: André F. Rendeiro, et al.
Published: (2020-01-01)

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
by: Lavinia Arseni, et al.
Published: (2025-01-01)

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
by: Sabah Kadri, et al.
Published: (2017-05-01)

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
by: Chaitra Ujjani, et al.
Published: (2018-04-01)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
by: Pin Lu, et al.
Published: (2021-02-01)

P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL
by: Carsten Niemann, et al.
Published: (2023-08-01)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
by: Caroline Dartigeas, et al.
Published: (2022-09-01)

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
by: Simon Schliffke, et al.
Published: (2018-04-01)

The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype
by: Yu Aruga, et al.
Published: (2024-06-01)

The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
by: Alexandria P. Eiken, et al.
Published: (2024-08-01)

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
by: Kallesh D. Jayappa, et al.
Published: (2017-06-01)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
by: Shaqir Qerama, et al.
Published: (2023-08-01)

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
by: Maria Tariq Siddiqui, et al.
Published: (2021-01-01)

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)Research in context
by: Pau Abrisqueta, et al.
Published: (2024-07-01)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
by: Arnon Kater, et al.
Published: (2023-08-01)

A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL
by: Can Chen, et al.
Published: (2023-03-01)

Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
by: Kathleen L Deering, et al.
Published: (2022-01-01)

Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study
by: Kathleen L. Deering, et al.
Published: (2022-01-01)

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

P1596: PREDIAGNOSTIC ANTIMICROBIAL USE IN CLL, MM, FL AND DLBCL
by: E. M. Packness, et al.
Published: (2022-06-01)

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
by: Paul J. Hengeveld, et al.
Published: (2025-01-01)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
by: Petra Langerbeins, et al.
Published: (2023-08-01)

Rare but Serious: Ibrutinib Induced Liver Failure
by: Fleur S. Kleijwegt, et al.
Published: (2019-12-01)